About Fulgent Genetics
Fulgent Genetics is a premier, full-service genomic testing company founded in 2011 and built around a foundational next-generation sequencing (NGS) technology platform. The company has evolved into a comprehensive precision medicine organization focused on transforming patient care across multiple therapeutic areas including oncology, anatomic pathology, infectious diseases, rare diseases, and reproductive health. Fulgent offers an unrivaled catalog of genetic testing options, including over 18,000 single gene tests, 900+ rare disease panels, whole genome sequencing, whole genome copy number variation analysis, mitochondrial sequencing, and customizable NGS panels. The company was the first clinical laboratory in the United States to offer copy number variation detection using NGS technology. All testing is performed at their six CLIA-certified and CAP-accredited laboratories across the United States, with all data analysis conducted on private servers. Recently, Fulgent has expanded beyond diagnostics into therapeutic development, creating drug candidates for treating cancers using a novel nanoencapsulation and targeted therapy platform. The company has also completed strategic acquisitions including Bako Diagnostics and StrataDx to strengthen its capabilities. Through flexible testing options, best-in-class service, and a commitment to innovation, Fulgent aims to redefine how medicine is managed for patients and clinicians while becoming a fully integrated precision medicine company.
Mission & Story
Mission
Our mission is to develop flexible and affordable diagnostics and therapeutics that improve the everyday lives of those around us.
Founding Story
Founded in 2011, Fulgent has evolved into a premier, full-service genomic testing company built around a foundational technology platform. The company was the first clinical laboratory to offer copy number variation detection using NGS technology in the United States.
Clinical Focus
Medical conditions and clinical areas addressed by Fulgent Genetics.
Who It Serves
Milestones & Awards
Recent Milestones
Completed acquisition of Bako Diagnostics and StrataDx. Expanded into therapeutic development with novel nanoencapsulation and targeted therapy platform for cancer treatment.
Awards & Recognition
First clinical laboratory in the United States to offer copy number variation detection using NGS technology
Key Partnerships
Company Details
- Founded
- 2011
- Headquarters
- El Monte, CA, USA
Work here?
Claim this listing to update company information and connect with our audience.
Claim This ListingSecurity & Compliance
Official Sources
Similar Companies in this Market
View all 60 →
23andMe
23andMe uses AI to analyze genetic data and provide personalized health summaries, risk assessments, and wellness recommendations based on genomic insights.
2bPrecise
AI-powered precision medicine platform for personalized treatment recommendations and genomic analysis.
ACT Genomics
AI-powered genomic analysis platform for precision medicine and personalized treatment recommendations.
Adaptive Biotechnologies
Adaptive Biotechnologies uses AI and machine learning to decode the immune system and identify disease-specific immune signatures for diagnosis and personalized treatment.
Ambry Genetics
Ambry Genetics is a leading clinical genetic testing laboratory specializing in hereditary cancer, rare disease, cardiology, and neurology testing. The company provides advanced genetic testing solutions with paired DNA/RNA analysis and comprehensive patient support programs.
Ataraxis
Ataraxis develops AI-native precision medicine tools that predict patient outcomes and treatment response in oncology. Their flagship product, Ataraxis Breast, provides clinically validated prognostic and predictive tests for breast cancer using multi-modal AI analysis of pathology images and clinical data.
Avenda Health
Avenda Health develops Unfold AI, an FDA-cleared artificial intelligence platform that creates 3D cancer estimation maps for prostate cancer. The technology analyzes standard-of-care data (MRI, biopsy, pathology, PSA) to visualize cancer location and extent, helping physicians make more informed treatment decisions and improve patient outcomes.
Base Genomics
Base Genomics appears to be a company in the Precision Medicine & Genomics space, but the scraped website content is empty or inaccessible, preventing detailed analysis of their offerings and target market.
Data Accuracy Notice: Company information on HealthAI Central is compiled from public sources and updated regularly. While we strive for accuracy, details such as funding figures, employee counts, and product offerings may change. We recommend verifying critical information directly with the company before making business decisions.